SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-20-008881
Filing Date
2020-08-11
Accepted
2020-08-11 17:22:48
Documents
19
Period of Report
2020-08-11
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT azrx8k_aug112020.htm 8-K 28419
2 PRESS RELEASE ex99-1.htm EX-99.1 26049
3 CORPORATE PRESENTATION ex99-2.htm EX-99 15315
4 IMAGE ex99-2000.jpg GRAPHIC 52251
5 IMAGE ex99-2001.jpg GRAPHIC 191810
6 IMAGE ex99-2002.jpg GRAPHIC 92849
7 IMAGE ex99-2003.jpg GRAPHIC 73139
8 IMAGE ex99-2004.jpg GRAPHIC 94065
9 IMAGE ex99-2005.jpg GRAPHIC 79469
10 IMAGE ex99-2006.jpg GRAPHIC 83906
11 IMAGE ex99-2007.jpg GRAPHIC 58526
12 IMAGE ex99-2008.jpg GRAPHIC 73471
13 IMAGE ex99-2009.jpg GRAPHIC 77925
14 IMAGE ex99-2010.jpg GRAPHIC 72037
15 IMAGE ex99-2011.jpg GRAPHIC 96368
16 IMAGE ex99-2012.jpg GRAPHIC 49702
17 IMAGE ex99-2013.jpg GRAPHIC 89651
18 IMAGE ex99-2014.jpg GRAPHIC 78079
19 IMAGE ex99-2015.jpg GRAPHIC 52821
  Complete submission text file 0001654954-20-008881.txt   1885019
Mailing Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226
Business Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226 646-699-7855
AzurRx BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37853 | Film No.: 201093432
SIC: 2834 Pharmaceutical Preparations